Pharmexa A/S (CPH:PHARMX) will release the fourth quarter earnings for 2007 on March 3.
Based in Denmark, Pharmexa A/S is a biotechnology company engaged in the field of immunotherapy and vaccines to treat cancer and serious chronic and infectious diseases. The company portfolio includes several patented technology platforms in immunotherapy and vaccination, as well as candidates at development states ranging from early research to clinical trials in patients.
The company is active in strategic alliances with H. Lundbeck, Innogenetics and Bavarian Nordic.
For more Earnings related events or to post your own events, visit: